Related Experiment Video
Updated: Sep 22, 2025

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement
Philippe Généreux1, Philippe Pibarot2, Björn Redfors3
1Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA.
Insights
Aortic valve replacement (AVR) impacts cardiac damage progression. Worsening cardiac damage post-AVR independently predicts higher mortality and heart failure risk, emphasizing early intervention for better prognosis.
Area of Science:
- Cardiology
- Cardiac Surgery
- Interventional Cardiology
Background:
- The effect of aortic valve replacement (AVR) on extravalvular cardiac damage progression and its prognostic significance remains unclear.
- Understanding these changes is crucial for optimizing patient outcomes after AVR.
Purpose of the Study:
- To investigate the evolution of cardiac damage following AVR.
- To determine the association between changes in cardiac damage and patient prognosis.
Main Methods:
- Pooled data from the PARTNER 2 and 3 trials included patients undergoing transcatheter or surgical AVR.
- Cardiac damage was staged at baseline and 1 year post-AVR.
- Proportional hazards models assessed the link between cardiac damage changes and 2-year outcomes.
Main Results:
- Among 1,974 patients, baseline cardiac damage varied, with most in stage 2 (51.4%).
- At 1 year, cardiac damage improved in ~15%, remained stable in ~60%, and worsened in ~25% of patients.
- One-year changes in cardiac damage independently predicted 2-year mortality (HR worsening: 1.95) and death/heart failure hospitalization (HR worsening: 2.25).
Conclusions:
- The extent of extravalvular cardiac damage and its change post-AVR are significant prognostic indicators.
- Earlier detection and intervention for aortic stenosis may prevent irreversible cardiac damage, improving global cardiac function and outcomes.
Background:
The impact of aortic valve replacement (AVR) on progression/regression of extravalvular cardiac damage and its association with subsequent prognosis is unknown.
Objectives:
The purpose of this study was to describe the evolution of cardiac damage post-AVR and its association with outcomes.
Methods:
Patients undergoing transcatheter or surgical AVR from the PARTNER (Placement of Aortic Transcatheter Valves) 2 and 3 trials were pooled and classified by cardiac damage stage at baseline and 1 year (stage 0, no damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary vasculature or tricuspid valve damage; and stage 4, right ventricular damage). Proportional hazards models determined association between change in cardiac damage post-AVR and 2-year outcomes.
Results:
Among 1,974 patients, 121 (6.1%) were stage 0, 287 (14.5%) stage 1, 1,014 (51.4%) stage 2, 412 (20.9%) stage 3, and 140 (7.1%) stage 4 pre-AVR. Two-year mortality was associated with extent of cardiac damage at baseline and 1 year. Compared with baseline, cardiac damage improved in ∼15%, remained unchanged in ∼60%, and worsened in ∼25% of patients at 1 year. The 1-year change in cardiac damage stage was independently associated with mortality (adjusted HR for improvement: 0.49; no change: 1.00; worsening: 1.95; P = 0.023) and composite of death or heart failure hospitalization (adjusted HR for improvement: 0.60; no change: 1.00; worsening: 2.25; P < 0.001) at 2 years.
Conclusions:
In patients undergoing AVR, extent of extravalvular cardiac damage at baseline and its change at 1 year have important prognostic implications. These findings suggest that earlier detection of aortic stenosis and intervention before development of irreversible cardiac damage may improve global cardiac function and prognosis. (PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk [PII A], NCT01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B [PARTNERII B], NCT02184442; and PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3], NCT02675114).
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation III: Medical Management
Aortic Regurgitation IV: Nursing Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Stenosis I: Introduction

